| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions. | 视觉障碍
> 视觉障碍 | 监管合作伙伴关系
> 与监管机构合作 | Do not know | National | Sometimes | 119063928324 |
| Submissions to the provincial government and advisory briefs to the to INESSS [Institut National d'Excellence en Santé et en Services Sociaux – National Institute of Excellence in Health and Social Services]. | 视觉障碍
> 黄斑变性 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | Regional | Regularly | 115043530962 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 神经系统
> 多发性硬化症 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Regularly | 115059223657 |
| Patient Group Evidence submissions to Canada's Drug Agency (CADTH [Canadian Agency for Drugs and Technologies in Health]), INESSS [Institut national d'excellence en santé et en services sociaux - National Institute of Excellence in Health and Social Services] and BC [British Columbia] Pharmacare. | 呼吸系统
> 慢性阻塞性肺疾病（COPD） | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Sometimes | 119013149214 |
| Canadian Drug Agency patient submissions. INESSS [Institut national d'excellence en santé et en services sociaux] (Quebec) patient submissions. | 呼吸系统
> 哮喘和过敏 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119021123567 |
| Canadian Drug Agency patient submissions. | 呼吸系统
> 哮喘和过敏 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119021123567 |
| HTA [Health Technology Assessment] submissions. | 皮肤
> 皮肤病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119022981107 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. We write submissions to the HCA [Health Canada Assessment] process (CDA [Canada's Drug Agency] and INESSS [National Institute for Excellence in Health and Social Services]). | 癌症
> 癌症：血液 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Regularly | 119031899906 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | 胃肠道
> 胃肠道：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119037340441 |
| We do regular submissions for HTA [Health Technology Assessment]. | 胃肠道
> 胃肠道：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119037340441 |
| CDA [Canada's Drug Agency] and pCPA [pan-Canadian Pharmaceutical Alliance]. | 心血管
> 心血管和心脏疾病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | International | Sometimes | 119040619515 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 总体健康
> 总体健康 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Sometimes | 119042243488 |
| Through the CDA-AMC [Canadian Drug Agency – Agence des médicaments du Canada]. | 癌症
> 癌症：皮肤 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Regularly | 119042855470 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | 患者权益倡导
> 健康活动人士 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | 患者权益倡导
> 健康活动人士 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Part of CDA [Canada’s Drug Agency] review process. | 呼吸系统
> 肺部疾病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | Regional | Rarely | 119044465336 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors. | 稀有
> 罕见病：其他 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Sometimes | 119045262810 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | 癌症
> 癌症：乳腺癌 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119049015873 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | 癌症
> 癌症：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | Regional | Sometimes | 119050786265 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | 皮肤
> 脱发 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Sometimes | 119050829703 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | 呼吸系统
> 肺纤维化 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119050864232 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | 癌症
> 癌症：血液 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Regularly | 119050868250 |
| HTA [Health Technology Assessment] submissions for new treatments. | 癌症
> 癌症：膀胱癌 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Sometimes | 119051388329 |
| We provide patient input to Canada's Drug Agency when they are deciding whether or not to recommend public reimbursement for new drugs. | 视觉障碍
> 视觉障碍 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119061542318 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 癌症
> 癌症：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Regularly | 119068300611 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | 稀有
> 庞贝病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100 | National | Rarely | 119070062251 |
| We submit HTA [Health Technology Assessment] submissions to Canada Drug Agency. | 呼吸系统
> 肺纤维化 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119070095029 |
| CDA [Canadian Drug Agency – Agence des médicaments du Canada], INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 癌症
> 癌症：结直肠癌 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Regularly | 119070177334 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | 总体健康
> 肥胖症 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | International | Regularly | 119071517799 |
| CDA [Canada's Drug Agency] AMC [Agence des médicaments du Canada], INESSS [National Institute of Excellence in Health and Social Services]. | 总体健康
> 肥胖症 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119072155321 |
| HTA [Health Technology Assessment] assessments and reimbursement reviews. | 患者教育
> 患者教育 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Do not know | National | Sometimes | 119073221885 |
| We participated in a Canada Drug Agency review of COPD [Chronic Obstructive Pulmonary Disease] medication access recently. | 呼吸系统
> 肺部疾病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Do not know | National | Rarely | 119074014255 |
| Patient submissions to CDA [Canada's Drug Agency]. | 风湿性
> 狼疮 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | 视觉障碍
> 视觉障碍 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Do not know | National | Regularly | 119076796006 |
| We fully support new technologies and therapies to Health Canada. | 残疾
> 残疾：其他 | 监管合作伙伴关系
> 为营销授权申报做出贡献 | 5,000 | National | Regularly | 119070019511 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | 老年人
> 老年人 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100,000 | National | Regularly | 119020601606 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | 癌症
> 癌症：乳腺癌 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100,000 | National | Regularly | 119049015873 |
| Represent patient issues to regulators. | 稀有
> 罕见病：血液 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | We do not communicate with patients directly | National | Regularly | 119078414468 |
| Patients participate in Town Halls where some of these issues are addressed. | 血液
> 镰状细胞病 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | Regional | Rarely | 119026823537 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | 视觉障碍
> 黄斑变性 | 影响政策和立法
> 影响医疗保健政策和立法 | 100,000 | Regional | Regularly | 115043530962 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | 老年人
> 老年人 | 影响政策和立法
> 影响医疗保健政策和立法 | 10,000 | National | Regularly | 119044669631 |
| HTA submissions, other public consultations, awareness-building. | 皮肤
> 皮肤病：大多数类型 | 影响政策和立法
> 参与公众听证会和咨询 | 100,000 | National | Regularly | 119022981107 |
| Provincial Legislative Advocacy days yearly. | 风湿性
> 硬皮病 | 影响政策和立法
> 参与公众听证会和咨询 | 5,000 | National | Regularly | 119071951250 |
| Media representation and direct advocacy to provincial Members of Parliament. | 稀有
> 罕见病：遗传性 | 影响政策和立法
> 动员议员和政治领导人 | 1,000 | Regional | Sometimes | 115035427287 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | 老年人
> 老年人 | 影响政策和立法
> 动员议员和政治领导人 | 100,000 | National | Regularly | 119020601606 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | 老年人
> 老年人 | 影响政策和立法
> 动员议员和政治领导人 | 10,000 | National | Regularly | 119044669631 |
| Getting Besrem [immunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | 癌症
> 癌症：血液 | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | 1,000 | National | Sometimes | 119022124095 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | 视觉障碍
> 视觉障碍 | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | Do not know | National | Regularly | 119076796006 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | 癌症
> 癌症：血液 | 定价与可负担性倡导
> 倡导公平的药品定价 | 5,000 | National | Sometimes | 119020401468 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | 患者权益倡导
> 健康活动人士 | 定价与可负担性倡导
> 倡导公平的药品定价 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | 神经系统
> 癫痫 | 定价与可负担性倡导
> 倡导公平的药品定价 | 5,000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | 癌症
> 癌症：大多数类型 | 定价与可负担性倡导
> 倡导公平的药品定价 | 1,000 | National | Regularly | 119068300611 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective and have written numerous submissions to the authorities about drug access and pricing. | 癌症
> 癌症：血液 | 定价与可负担性倡导
> 倡导公平的药品定价 | 5,000 | National | Regularly | 119068939499 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | 稀有
> 庞贝病 | 定价与可负担性倡导
> 倡导公平的药品定价 | 100 | National | Rarely | 119070062251 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | 癌症
> 癌症：血液 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 5,000 | National | Sometimes | 119020401468 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance, alliance of Canada's federal, provincial, and territorial public drug plans that negotiates drug prices on behalf of public payers.]. | 免疫
> 原发性免疫缺陷病 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 5,000 | National | Sometimes | 119044550257 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | 老年人
> 老年人 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 10,000 | National | Regularly | 119044669631 |
| ... In the past, we have also advocated directly with the pCPA [Provincial Council for Drug Programs], which negotiates drug prices, but this is not a regular occurrence. | 视觉障碍
> 视觉障碍 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 100,000 | National | Regularly | 119061542318 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. | 癌症
> 癌症：血液 | 定价与可负担性倡导
> 呼吁制造商降低销售价格 | 10,000 | National | Regularly | 119031899906 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | 免疫
> 原发性免疫缺陷病 | 定价与可负担性倡导
> 跟踪和监控药品定价/药品短缺 | 5,000 | National | Sometimes | 119044550257 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | 神经系统
> 癫痫 | 定价与可负担性倡导
> 跟踪和监控药品定价/药品短缺 | 5,000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | 癌症
> 癌症：大多数类型 | 定价与可负担性倡导
> 跟踪和监控药品定价/药品短缺 | 1,000 | National | Regularly | 119068300611 |
| Patient group submissions—not specific to pricing itself, but to approvals for coverage. | 心理健康
> 心理健康：情绪障碍 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 10,000 | National | Rarely | 119020492804 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | 免疫
> 原发性免疫缺陷病 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 5,000 | National | Sometimes | 119044550257 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access through Provincial-Territorial formularies. | 神经系统
> 癫痫 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | We do not communicate with patients directly | National | Regularly | 119045277128 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | 呼吸系统
> 肺纤维化 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100,000 | National | Regularly | 119050864232 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions often. | 视觉障碍
> 视觉障碍 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | Do not know | National | Sometimes | 119063928324 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | 稀有
> 庞贝病 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100 | National | Rarely | 119070062251 |
| HTA submissions, other public consultations, awareness-building. | 皮肤
> 皮肤病：大多数类型 | 定价与可负担性倡导
> 参与宣传活动 | 100,000 | National | Regularly | 119022981107 |
| Getting Besrem [mmunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | 癌症
> 癌症：血液 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | National | Sometimes | 119022124095 |
| We don't provide information for drug pricing, just advocacy for drug approvals or access. | 风湿性
> 狼疮 | 改善访问路径
> 促进公平获取药品/医疗保健 | 5,000 | Regional | No | 119022371395 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | 患者权益倡导
> 健康活动人士 | 改善访问路径
> 促进公平获取药品/医疗保健 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors [a form of anti-cancer treatment]. | 稀有
> 罕见病：其他 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | National | Sometimes | 119045262810 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | 神经系统
> 癫痫 | 改善访问路径
> 促进公平获取药品/医疗保健 | We do not communicate with patients directly | National | Regularly | 119045277128 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | 癌症
> 癌症：大多数类型 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | Regional | Sometimes | 119050786265 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | 癌症
> 癌症：血液 | 改善访问路径
> 促进公平获取药品/医疗保健 | 5,000 | National | Regularly | 119050868250 |
| We frequently advocate for the approval of new drugs for market access. | 视觉障碍
> 视觉障碍 | 改善访问路径
> 促进公平获取药品/医疗保健 | Do not know | National | Sometimes | 119063928324 |
| … and have written numerous submissions to the authorities about drug access and pricing. | 癌症
> 癌症：血液 | 改善访问路径
> 促进公平获取药品/医疗保健 | 5,000 | National | Regularly | 119068939499 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | 总体健康
> 肥胖症 | 改善访问路径
> 促进公平获取药品/医疗保健 | 100,000 | International | Regularly | 119071517799 |
| Patient submissions to CDA [Canada's Drug Agency]. Ongoing national advocacy for equitable access to care and treatment. | 风湿性
> 狼疮 | 改善访问路径
> 促进公平获取药品/医疗保健 | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We often focus on vaccines, but not only those. We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | 老年人
> 老年人 | 改善访问路径
> 倡导更广泛的疫苗获取渠道 | 10,000 | National | Regularly | 119044669631 |
| We provide patient input to CDA [Canada Drug Agency] when they are deciding whether or not to recommend public reimbursement for new drugs. We also provide input to provinces. | 视觉障碍
> 视觉障碍 | 改善访问路径
> 解决访问和管理方面的差距 | 100,000 | National | Regularly | 119061542318 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, we act as Canada's advocacy group on behalf of sarcoma cancer patients. | 癌症
> 癌症：肉瘤 | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 5,000 | National | Regularly | 119078449674 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | 患者权益倡导
> 健康活动人士 | 循证患者意见
> 利用患者洞察来指导决策 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | 皮肤
> 脱发 | 循证患者意见
> 利用患者洞察来指导决策 | 5,000 | National | Sometimes | 119050829703 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | 稀有
> 庞贝病 | 循证患者意见
> 利用患者洞察来指导决策 | 100 | National | Rarely | 119070062251 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | 总体健康
> 肥胖症 | 循证患者意见
> 利用患者洞察来指导决策 | 100,000 | International | Regularly | 119071517799 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | 患者权益倡导
> 健康活动人士 | 循证患者意见
> 向监管机构提供真实世界证据（RWE） | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| The lived experiences of patients are at the centre of Lupus Canada's work. | 风湿性
> 狼疮 | 循证患者意见
> 利用患者故事和亲身经历叙述 | Do not know | National | Regularly | 119041443233 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 总体健康
> 总体健康 | 循证患者意见
> 利用患者故事和亲身经历叙述 | 10,000 | National | Sometimes | 119042243488 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | 患者权益倡导
> 健康活动人士 | 循证患者意见
> 利用患者故事和亲身经历叙述 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We also submit on behalf of people with lived experience through the Health Technology Assessment opportunities with CAD-AMC [Canada's Drug Agency / l'Agence des médicaments du Canada (CDA-AMC)] and INESSS [Institut national d'excellence en santé et en services sociaux -National Institute of Excellence in Health and Social Services]. | 癌症
> 癌症：大多数类型 | 循证患者意见
> 利用患者故事和亲身经历叙述 | 1,000 | National | Regularly | 119068300611 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 癌症
> 癌症：大多数类型 | 循证患者意见
> 利用患者故事和亲身经历叙述 | 1,000 | National | Regularly | 119068300611 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | 患者权益倡导
> 健康活动人士 | 循证患者意见
> 开展调查/研究以生成数据 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members regularly participate in CDA [Canadian Drug Agency] surveys and sessions. | 视觉障碍
> 视觉障碍 | 循证患者意见
> 开展调查/研究以生成数据 | Do not know | National | Sometimes | 119063928324 |
| Representation, rights advocacy, and immigration support. | HIV
> HIV与性健康 | 机构治理
> 确保在政府咨询机构中的代表性 | 100 | National | Regularly | 115032094015 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | 胃肠道
> 胃肠道：大多数类型 | 机构治理
> 确保在政府咨询机构中的代表性 | 100,000 | National | Regularly | 119037340441 |
| ... been invited to national roundtables by governments and also by pharma, etc. | 老年人
> 老年人 | 机构治理
> 确保在政府咨询机构中的代表性 | 10,000 | National | Regularly | 119044669631 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective. | 癌症
> 癌症：血液 | 机构治理
> 确保在政府咨询机构中的代表性 | 5,000 | National | Regularly | 119068939499 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, We act as Canada's advocacy group on behalf of sarcoma cancer patientsw | 癌症
> 癌症：肉瘤 | 机构治理
> 确保在政府咨询机构中的代表性 | 5,000 | National | Regularly | 119078449674 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | 神经系统
> 癫痫 | 机构治理
> 在多利益相关方网络中高效协作 | We do not communicate with patients directly | National | Regularly | 119045277128 |
| Representation, rights advocacy, and immigration support. | HIV
> HIV与性健康 | 维护患者权益/提高生活质量
> 保护/改善患者体验 | 100 | National | Regularly | 115032094015 |
| We are a peer-led organization that advocates for one another on patients' rights, on care and treatment. | HIV
> HIV | 维护患者权益/提高生活质量
> 保护/改善患者体验 | 1,000 | Local | Regularly | 119045557717 |
互动
行动与倡导
36 提及
